• Citer

The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters

par Brouwers, Barbara;Bechter, Oliver;Bailur, Jithendra Kini;Kenis, Cindy;Laenen, Annouschka;Schöffski, Patrick;Pawelec, Graham;Journé, Fabrice ;Ghanem, Ghanem Elias ;Wildiers, Hans;Hatse, Sigrid;Dal Lago, Lissandra ;Neven, Patrick;Vuylsteke, Peter;Dalmasso, Bruna;Debrock, Guy;Van Den Bulck, Heidi;Smeets, Ann
Référence Oncotarget, 7, 21, page (29977-29988)
Publication Publié, 2016-05

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Purpose. This prospective observational study aimed to evaluate the impact of adjuvant chemotherapy on biological and clinical markers of aging and frailty. Methods. Women ≥ 70 years old with early breast cancer were enrolled after surgery and assigned to a chemotherapy (Docetaxel and Cyclophosphamide) group (CTG, n=57) or control group (CG, n=52) depending on their planned adjuvant treatment. Full geriatric assessment (GA) and Quality of Life (QoL) were evaluated at inclusion (T0), after 3 months (T1) and at 1 year (T2). Blood samples were collected to measure leukocyte telomere length (LTL), levels of interleukin-6 (IL-6) and other circulating markers potentially informative for aging and frailty: Interleukin-10 (IL- 10), Tumor Necrosis Factor Alpha (TNF-α), Insulin-like Growth Factor 1 (IGF-1), Monocyte Chemotactic Protein 1 (MCP-1) and Regulated on Activation, Normal T cell Expressed and Secreted (RANTES). Results. LTL decreased significantly but comparably in both groups, whereas IL-6 was unchanged at T2. However, IL-10, TNF-α, IGF-1 and MCP-1 suggested a minor biological aging effect of chemotherapy. Clinical frailty and QoL decreased at T1 in the CTG, but recovered at T2, while remaining stable in the CG. Conclusion. Chemotherapy (TC) is unlikely to amplify clinical aging or induce frailty at 1 year. Accordingly, there is no impact on the most established aging biomarkers (LTL, IL-6).